Nanobiotix, LianBio Join Forces to Develop, Commercialize Lead Oncology Product NBTXR3 in Asia
06:36 AM EDT, 05/12/2021 (MT Newswires) -- Nanobiotix (NBTX) is teaming up with biotechnology firm LianBio to develop and commercialize the former's lead oncology product candidate NBTXR3 in China and other markets in Asia.
Under the terms of the agreement announced Tuesday, LianBio will secure exclusive rights to develop and commercialize NBTXR3 in China, Hong Kong, Taiwan, Macau, South Korea, Singapore and Thailand.
Nanobiotix will receive a $20 million upfront payment and is entitled to receive up to an aggregate of $220 million in potential contingent, development, and commercialization milestone payments as well as tiered, low double-digit royalties based on net sales of NBTXR3 in the licensed territories.
LianBio will enroll 100 patients in the Nanobiotix global phase 3 registrational study evaluating NBTXR3 for patients with locally advanced head and neck squamous cell carcinoma. It also committed to enroll patients in four additional registrational studies across indications and therapeutic combinations potentially including immunotherapy, according to the news release.
Price: 14.35, Change: -0.74, Percent Change: -4.90